secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000059478-25-000129
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance
----------------------------------------------------------------

- Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.
- Reported EPS $3.06 (+23%); non-GAAP EPS $3.34 (+29%), including $1.72 IPR&D charges.
- Revenue guidance reaffirmed at $58.0-$61.0 billion for full-year 2025.
- Pipeline: positive Phase 3 for oral GLP-1 orforglipron in T2D; approvals in oncology/immunology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/0000059478-25-000129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947825000129/lly-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000059478-25-000129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer